MIRM
Mirum Pharmaceuticals, Inc.
$83.44
-1.63
(-1.92%)
Mkt Cap
5.42B
Volume
646,889
52W Range
63.23-130
Sector
Healthcare
Beta
0.49
EPS (TTM)
-14.56 USD
P/E Ratio
-168.06
Revenue (TTM)
618.07M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 521.31M | 336.89M | 186.37M | 77.06M | 19.14M | 0 | 0 | 0 |
| Net Income | (23.36M) | (87.94M) | (163.41M) | (135.66M) | (83.99M) | (103.27M) | (52.55M) | (17.35M) |
| EPS | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| Free Cash Flow | 54.87M | 9.33M | (91.05M) | (120.41M) | (151.78M) | (89.30M) | (39.64M) | (7.87M) |
| FCF / Share | 1.09 | 0.20 | -2.23 | -3.56 | -5.01 | -3.54 | -1.72 | -0.34 |
| Operating CF | 55.83M | 10.32M | (70.94M) | (120.14M) | (132.76M) | (89.08M) | (39.36M) | (373,000) |
| Total Assets | 842.81M | 670.75M | 646.62M | 352.91M | 294.65M | 240.86M | 146.71M | 51.98M |
| Total Debt | 319.45M | 317.76M | 308.14M | 2.19M | 2.61M | 3.26M | 3.65M | 0 |
| Cash & Equiv | 296.68M | 222.50M | 286.33M | 28.00M | 31.34M | 142.09M | 11.97M | 51.96M |
| Book Value | 314.69M | 225.64M | 248.67M | 142.04M | 120.21M | 172.09M | 130.35M | (10.32M) |
| Return on Equity | -0.07 | -0.39 | -0.66 | -0.96 | -0.70 | -0.60 | -0.40 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 176.24M | 159.88M | 148.93M | 133.01M | 127.78M | 111.58M | 99.41M | 90.38M | 77.88M | 69.22M | 69.55M | 47.73M |
| Net Income | (67.23M) | (790.15M) | (5.73M) | 2.90M | (5.86M) | (14.68M) | (23.79M) | (14.23M) | (24.64M) | (25.28M) | (35.66M) | (23.59M) |
| EPS | -1.06 | -13.43 | -0.12 | 0.05 | -0.12 | -0.30 | -0.49 | -0.30 | -0.52 | -0.54 | -0.71 | -0.57 |
| Free Cash Flow | (273.70M) | (229.43M) | 5.47M | 39.49M | 11.91M | (2.00M) | (5.09M) | (6.20M) | (14.58M) | 15.20M | (21.62M) | (18.22M) |
| FCF / Share | -4.32 | -3.90 | 0.11 | 0.69 | 0.24 | -0.04 | -0.11 | -0.13 | -0.31 | 0.32 | -0.46 | -0.44 |
| Operating CF | (273.01M) | (228.76M) | 6.07M | 39.68M | 12.04M | (1.96M) | (5.07M) | 3.98M | (3.80M) | 15.21M | (16.62M) | (18.22M) |
| Total Assets | 1.04B | 890.92M | 842.81M | 785.12M | 725.83M | 690.25M | 670.75M | 667.89M | 660.75M | 651.96M | 646.62M | 650.64M |
| Total Debt | 760.54M | 323.78M | 319.45M | 318.76M | 318.90M | 317.16M | 317.76M | 317.65M | 316.56M | 307.52M | 308.14M | 307.97M |
| Cash & Equiv | 330.73M | 324.91M | 296.68M | 282.02M | 228.12M | 211.82M | 222.50M | 222.97M | 233.25M | 302.84M | 286.33M | 303.06M |
| Book Value | (10.42M) | 242.49M | 314.69M | 292.05M | 255.16M | 233.26M | 225.64M | 232.02M | 228.99M | 234.60M | 248.67M | 269.08M |
| Return on Equity | N/A | -3.26 | -0.02 | 0.01 | -0.02 | -0.06 | -0.11 | -0.06 | -0.11 | -0.11 | -0.14 | -0.09 |
MIRM News
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Rated “Moderate Buy” by Wall Street Brokerages
Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript
Mirum Pharmaceuticals’ LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases